IOC Executive Board meeting 35 December 2024 Information for the media
25 November 2024 - The International Olympic Committee (IOC) Executive Board (EB)…
FOXO TECHNOLOGIES INC., CONFIRMS DETAILS OF SPECIAL MEETING OF SHAREHOLDERS ON NOVEMBER 29, 2024.
MINNEAPOLIS, MN, Nov. 25, 2024 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (NYSE American: FOXO) (the…
Rakovina Therapeutics Announces Upcoming Poster Presentation at the 29th Annual Society for Neuro-Oncology Meeting in Houston, Texas
November 20, 2024 16:30 ET | Source: Rakovina Therapeutics Inc VANCOUVER, British…
Pliant Therapeutics Presents Data from its Bexotegrast Program at The Liver Meeting 2024
November 18, 2024 18:00 ET | Source: Pliant Therapeutics, Inc. INTEGRIS-PSC featured…
Protara Therapeutics to Present New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC at the 25th Annual Meeting of the Society of Urologic Oncology
November 15, 2024 17:52 ET | Source: Protara Therapeutics NEW YORK, Nov.…
Xtract One Announces Results of Voting at theAnnual General Meeting of Shareholders
TORONTO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Xtract One Technologies (TSX: XTRA)(OTCQX: XTRAF)(FRA:…
TB Alliance Joins Indonesia’s High-Level Meeting on TB
Announces Strategy to Accelerate Efforts Toward Ending the TB Pandemic BALI, Indonesia,…
TB Alliance Joins Indonesia’s High-Level Meeting on TB
Announces Strategy to Accelerate Efforts Toward Ending the TB Pandemic BALI, Indonesia,…
Fate Therapeutics Highlights Cancer-selective, HER2-Targeting Profile of FT825 / ONO-8250 CAR T-cell Product Candidate for Treatment of Advanced Solid Tumors at 2024 SITC Annual Meeting
Novel H2CasMab-2 Antigen Binding Domain Shown to Preferentially Target HER2 Expressed on…
Replimune Presents Late-Breaking Abstract Featuring Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024)
November 09, 2024 13:00 ET | Source: Replimune Group Inc Oral presentation…